Published in Respir Res on March 10, 2015
Left ventricular heart failure and pulmonary hypertension†. Eur Heart J (2015) 0.95
Circulating Angiopoietin-1 Is Not a Biomarker of Disease Severity or Prognosis in Pulmonary Hypertension. PLoS One (2016) 0.75
Use of ECG and Other Simple Non-Invasive Tools to Assess Pulmonary Hypertension. PLoS One (2016) 0.75
Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol (2013) 8.29
Primary pulmonary hypertension. A national prospective study. Ann Intern Med (1987) 6.80
Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J (2009) 6.64
Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol (2013) 4.89
Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet (2011) 4.59
The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest (2010) 3.02
Lung function and exercise gas exchange in chronic heart failure. Circulation (1997) 2.32
The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. Eur Respir J (2012) 2.30
Reading pulmonary vascular pressure tracings. How to handle the problems of zero leveling and respiratory swings. Am J Respir Crit Care Med (2014) 2.14
Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol (2013) 2.07
Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. J Am Coll Cardiol (1997) 2.05
Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med (2012) 2.00
Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest (2009) 1.99
Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol (2009) 1.78
The clinical utility of arterialized earlobe capillary blood in the assessment of patients for long-term oxygen therapy. Respir Med (2001) 1.72
Arterial versus capillary blood gases: a meta-analysis. Respir Physiol Neurobiol (2006) 1.71
Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol (2012) 1.48
Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation (1997) 1.46
Enhanced ventilatory response to exercise in patients with chronic heart failure and preserved exercise tolerance: marker of abnormal cardiorespiratory reflex control and predictor of poor prognosis. Circulation (2001) 1.33
Clinical relevance of autonomic nervous system disturbances in pulmonary arterial hypertension. Eur Respir J (2009) 1.20
Comparison of simultaneously obtained arterial and capillary blood gases in pediatric intensive care unit patients. Crit Care Med (1997) 1.17
Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension. Eur Respir J (2007) 0.92
Zero reference level for right heart catheterisation. Eur Respir J (2013) 0.91
Earlobe arterialized capillary blood gas analysis in the intensive care unit: a pilot study. Ann Intensive Care (2014) 0.90
Pulmonary vascular diseases. Compr Physiol (2011) 0.83
Reliance on end-expiratory wedge pressure leads to misclassification of pulmonary hypertension. Eur Respir J (2014) 0.82
Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med (2008) 19.93
Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol (2009) 5.31
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med (2013) 5.22
Inhaled iloprost for severe pulmonary hypertension. N Engl J Med (2002) 3.90
Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation (2013) 3.90
Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med (2007) 2.97
Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation. Am J Respir Crit Care Med (2012) 2.86
Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation (2006) 2.67
Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol (2009) 2.57
Practice and perception--a nationwide survey of therapy habits in sepsis. Crit Care Med (2008) 2.43
Rethinking the concepts of community-acquired and health-care-associated pneumonia. Lancet Infect Dis (2010) 2.37
Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev (2012) 2.31
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med (2015) 2.23
Community-acquired Legionella pneumonia: new insights from the German competence network for community acquired pneumonia. Clin Infect Dis (2008) 2.20
Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med (2010) 2.19
Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Respir Crit Care Med (2014) 2.16
Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation (2003) 2.12
Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Evid Based Child Health (2013) 2.12
Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ. Intensive Care Med (2007) 2.06
Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation (2011) 1.92
Fluid replacement with hydroxyethyl starch in critical care--a reassessment. Dtsch Arztebl Int (2013) 1.87
Vascular complications in patients undergoing femoral cannulation for extracorporeal membrane oxygenation support. Ann Thorac Surg (2011) 1.81
Life after corpse engulfment: phagocytosis of apoptotic cells leads to VEGF secretion and cell growth. FASEB J (2004) 1.74
Alpha-1 antitrypsin deficiency: pathogenesis, clinical presentation, diagnosis, and treatment. Am J Med (2008) 1.70
Resident alveolar macrophages are replaced by recruited monocytes in response to endotoxin-induced lung inflammation. Am J Respir Cell Mol Biol (2006) 1.70
Nanoparticle-based diagnosis and therapy. Curr Drug Targets (2006) 1.70
Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol (2008) 1.69
Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med (2010) 1.69
Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis (2012) 1.67
Hospital Incidence and Mortality Rates of Sepsis. Dtsch Arztebl Int (2016) 1.65
Adult patients with nosocomial pneumonia: epidemiology, diagnosis, and treatment. Dtsch Arztebl Int (2013) 1.65
Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. Eur Respir J (2012) 1.63
Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med (2015) 1.62
Long-term outcome after pulmonary retransplantation. J Thorac Cardiovasc Surg (2006) 1.59
New horizons in early stage COPD--improving knowledge, detection and treatment. Respir Med (2011) 1.56
Absence of Kaposi's sarcoma-associated herpesvirus in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med (2005) 1.55
Protease-activated receptor-1 in human lung fibroblasts mediates a negative feedback downregulation via prostaglandin E2. Am J Physiol Lung Cell Mol Physiol (2004) 1.53
Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents (2008) 1.52
C1-esterase-inhibitor for primary graft dysfunction in lung transplantation. Transplantation (2014) 1.49
α-1-antitrypsin inhibits acute liver failure in mice. Hepatology (2014) 1.49
Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol (2012) 1.48
Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a US health system perspective. Clin Chem Lab Med (2015) 1.48
Adrenomedullin refines mortality prediction by the BODE index in COPD: the "BODE-A" index. Eur Respir J (2013) 1.45
Bronchiectasis--diagnosis and treatment. Dtsch Arztebl Int (2011) 1.43
Macrophage Turnover Kinetics in the Lungs of Mice Infected with Streptococcus pneumoniae. Am J Respir Cell Mol Biol (2007) 1.42
Lung-specific overexpression of CC chemokine ligand (CCL) 2 enhances the host defense to Streptococcus pneumoniae infection in mice: role of the CCL2-CCR2 axis. J Immunol (2007) 1.41
Allogeneic CD4+CD25high T cells regulate obliterative bronchiolitis of heterotopic bronchus allografts in both porcinized and humanized mouse models. Transplantation (2015) 1.40
Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis (2009) 1.40
Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ (2003) 1.37
Pivotal role of cathepsin K in lung fibrosis. Am J Pathol (2004) 1.35
Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med (2015) 1.34
Bridge to lung transplantation with the novel pumpless interventional lung assist device NovaLung. J Thorac Cardiovasc Surg (2006) 1.33
Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol (2005) 1.32
The discovery of α1-antitrypsin and its role in health and disease. Respir Med (2011) 1.30
Inter-disease comparison of research quantity and quality: bronchial asthma and chronic obstructive pulmonary disease. J Asthma (2009) 1.28
Important role for CC chemokine ligand 2-dependent lung mononuclear phagocyte recruitment to inhibit sepsis in mice infected with Streptococcus pneumoniae. J Immunol (2009) 1.27
Risk factors for COPD spirometrically defined from the lower limit of normal in the BOLD project. Eur Respir J (2011) 1.26
Health-related quality of life in two hundred-eighty lung transplant recipients. J Heart Lung Transplant (2005) 1.25
Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment. Am J Pathol (2011) 1.23
Importance of CXC chemokine receptor 2 in alveolar neutrophil and exudate macrophage recruitment in response to pneumococcal lung infection. Infect Immun (2010) 1.23
Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J (2007) 1.23
Nanomedicine for respiratory diseases. Eur J Pharmacol (2006) 1.23
Correlation between chronic obstructive pulmonary disease and obstructive sleep apnea syndrome in a general population in Iran. J Res Med Sci (2011) 1.22
Nursing-home-acquired pneumonia in Germany: an 8-year prospective multicentre study. Thorax (2011) 1.22
Virus-associated hemophagocytic syndrome as a major contributor to death in patients with 2009 influenza A (H1N1) infection. Crit Care (2011) 1.21
Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients. Am J Respir Crit Care Med (2010) 1.21
Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: prospective cohort study. BMJ (2012) 1.20
Analysis of research output parameters: density equalizing mapping and citation trend analysis. BMC Health Serv Res (2009) 1.19
The inflammatory versus constitutive trafficking of mononuclear phagocytes into the alveolar space of mice is associated with drastic changes in their gene expression profiles. J Immunol (2005) 1.19
Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study. Transplantation (2009) 1.17
Altered expression of membrane-bound and soluble CD95/Fas contributes to the resistance of fibrotic lung fibroblasts to FasL induced apoptosis. Respir Res (2005) 1.17
The pulmonary immune effects of mechanical ventilation in patients undergoing thoracic surgery. Anesth Analg (2005) 1.16
Cost analyses of community-acquired pneumonia from the hospital perspective. Chest (2005) 1.15
Plexiform vasculopathy of severe pulmonary arterial hypertension and microRNA expression. J Heart Lung Transplant (2012) 1.15
Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir Res (2009) 1.12
Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? J Antimicrob Chemother (2006) 1.12
Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med (2008) 1.12
Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J (2012) 1.11
Development of rheumatoid nodules during anti-tumor necrosis factor alpha therapy with etanercept. Arthritis Rheum (2002) 1.11
Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J (2012) 1.11
Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest (2005) 1.11
Burden and trends of hospitalisations associated with pulmonary non-tuberculous mycobacterial infections in Germany, 2005-2011. BMC Infect Dis (2013) 1.10
Role of Mincle in alveolar macrophage-dependent innate immunity against mycobacterial infections in mice. J Immunol (2012) 1.10
Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother (2006) 1.09
Atrial flutter and fibrillation in patients with pulmonary hypertension. Int J Cardiol (2012) 1.09
Importance of phosphoinositide 3-kinase gamma in the host defense against pneumococcal infection. Am J Respir Crit Care Med (2007) 1.09
Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy. Am Heart J (2005) 1.09
Multicentre European study for the treatment of advanced emphysema with bronchial valves. Eur Respir J (2012) 1.09
Bronchiectasis-associated hospitalizations in Germany, 2005-2011: a population-based study of disease burden and trends. PLoS One (2013) 1.08
Fluoroquinolone-resistant Streptococcus pneumoniae. Emerg Infect Dis (2006) 1.08
Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int J Antimicrob Agents (2009) 1.08
Scientometric analysis and combined density-equalizing mapping of environmental tobacco smoke (ETS) research. PLoS One (2010) 1.08